Abstract
Astrocytoma constitutes the most noted malignancies of the central nervous system with worse clinical outcomes in grade IV astrocytoma or glioblastoma multiforme. Owing to poor clinical outcomes with existing therapeutic regime, there is a need to revisit the initial course of treatment. Statistical information of clinicopathological parameters could be used to understand the spread of disease and, in turn, to formulate updated treatment management. In the present study, we have seen anatomic distribution of astrocytoma subtypes in a group of 479 patients and correlated it with survival outcomes. Anatomic location was confirmed by MRI (magnetic resonance imaging) images. A registry of patients was maintained with clinicopathological details as tumor type, location, age/sex, and survival after surgery. We have observed overall survival particulars in patients diagnosed with astrocytoma. Our findings highlight that in total cases, tumor location was anatomically dominated by frontal and temporal lobes. Survival analysis in high-grade (grade III, p = 0.03; grade IV, p = 0.01) astrocytic tumors confirms poor outcomes with temporal, parietal, and occipital location as compared to frontal lobe. Overall survival study demonstrates glioblastoma multiforme (GBM) was associated with worse prognosis as compared to astrocytoma subtypes (p < 0.0001). In high-grade astrocytomas, anaplastic astrocytoma was found with 34 months of median survival age while 14 months in the case of patients with glioblastoma multiforme. In conclusion, we report dismal prognosis in parietal, temporal, and occipital lobes in grade II, grade III, and grade IV astrocytoma patients. Among astrocytoma subtypes, patients with glioblastoma multiforme were associated with worse survival outcomes. We uniquely feature the survival of astrocytoma patients for the first time and observe GBM patients have slightly longer survival.
Similar content being viewed by others
References
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. https://doi.org/10.1007/s00401-007-0243-4
Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncology 14(Suppl 5):v1–v49. https://doi.org/10.1093/neuonc/nos218
Baldi I, Gruber A, Alioum A, Berteaud E, Lebailly P, Huchet A, Tourdias T, Kantor G, Maire JP, Vital A, Loiseau H, and the Gironde TSNC Registry Group, Champeaux K, Dhauteribes M, Eimer S, Gimbert E, Liguoro D, Monteil P, Penchet G, San-Galli F, Vignes J (2011) Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro-Oncology 13(12):1370–1378. https://doi.org/10.1093/neuonc/nor120
van den Bent MJ, Bromberg JE (2015) Neuro-oncology: the many challenges of treating elderly glioblastoma patients. Nat Rev Neurol 11(7):374–375. https://doi.org/10.1038/nrneurol.2015.82
Walid MS (2008) Prognostic factors for long-term survival after glioblastoma. Perm J 12(4):45–48
Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncology 6(3):227–235
Deshpande RP, Babu D, Panigrahi M, Chandra Sekhar YB, Prakash Babu P (2016) Brain tumors incidences and a retrospective clinical analysis from a tertiary hospital in India. J Neuro-Oncol 129(2):383–387. https://doi.org/10.1007/s11060-016-2183-0
Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S et al (2006) Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65(9):846–854
Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U (2000) Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neuro-Oncol 48(2):89–94
Wrensch M, Minn Y, Chew T, Bondy M, Berger MS (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 4(4):278–299
Peters O, Gnekow AK, Rating D, Wolff JE (2004) Impact of location on outcome in children with low-grade oligodendroglioma. Pediatr Blood Cancer 43(3):250–256. https://doi.org/10.1002/pbc.20111
Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y (1994) Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neuro-Oncol 21(2):177–185
Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, Weinstein AS, Nelson DF (1993) Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26(2):239–244
Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100(12):2622–2626. https://doi.org/10.1002/cncr.20297
Larjavaara S, Mantyla R, Salminen T, Haapasalo H, Raitanen J, Jaaskelainen J et al (2007) Incidence of gliomas by anatomic location. Neuro-Oncology 9(3):319–325. https://doi.org/10.1215/15228517-2007-016
Laigle-Donadey F, Martin-Duverneuil N, Lejeune J, Criniere E, Capelle L, Duffau H, Cornu P, Broet P, Kujas M, Mokhtari K, Carpentier A, Sanson M, Hoang-Xuan K, Thillet J, Delattre JY (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63(12):2360–2362
Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161(1):313–319. https://doi.org/10.1016/S0002-9440(10)64183-1
Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61(18):6713–6715
Ali Kahn A, O'Brien DF, Kelly P, Phillips JP, Rawluk D, Bolger C, Pidgeon CN (2003) The anatomical distribution of cerebral gliomas in mobile phone users. Ir Med J 96(8):240–242
Liu TT, Achrol AS, Mitchell LA, Du WA, Loya JJ, Rodriguez SA et al (2016) Computational identification of tumor anatomic location associated with survival in 2 large cohorts of human primary glioblastomas. AJNR Am J Neuroradiol 37(4):621–628. https://doi.org/10.3174/ajnr.A4631.
Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62(4):753–764; discussion 264-6. https://doi.org/10.1227/01.neu.0000318159.21731.cf
Colen RR, Vangel M, Wang J, Gutman DA, Hwang SN, Wintermark M et al (2014) Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. BMC Med Genet 7:30. https://doi.org/10.1186/1755-8794-7-30
Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, Berger MS (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro-Oncology 9(4):424–429. https://doi.org/10.1215/15228517-2007-023
Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS (2016) Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). J Neuro-Oncol 130(1):31–42. https://doi.org/10.1007/s11060-016-2217-7
Acknowledgements
The authors acknowledge KFRC, KIMS for the ethical permission and for diagnosis and histopathology of tissues, and Dr. M. Sailaja, Head, Department of Pathology.
Funding
The authors thank the financial assistance from the Department of Science and Technology (DST-India) (Grant no. SB/EMEQ-257/2013, SR/CSRI/196/2016), the Department of Biotechnology (DBT-India) (Grant no. BT/PR18168/MED/29/1064/2016, BT/PR13111/MED/29/149/2009), and the University with Potential for Excellence (UPE-India) (Grant no. UH/UGC/UPE-2/Interface studies/ Research Projects/B1.4, UH/UPE-2/28/2015) for lab funding. RDP is thankful to the Department of Biotechnology (DBT-India) (Award no. DBT JRF/2011–12/95) for student fellowship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Ethical Approval
The present studies involving human participants were approved by the Institutional Ethics Committee (ICE), University of Hyderabad and KIMS Foundation Research Centre (KFRC), KIMS, Secunderabad, India. All subjects participating were completely anonymized.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Deshpande, R.P., Y. B. V. K., C., Panigrahi, M. et al. Prognostic Significance of Anatomic Origin and Evaluation of Survival Statistics of Astrocytoma Patients—a Tertiary Experience. Indian J Surg Oncol 10, 55–60 (2019). https://doi.org/10.1007/s13193-018-0820-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-018-0820-0